The genetic landscape of clinical resistance to RAF inhibition in melanoma.
Eliezer Mendel Van Allen
No relevant relationships to disclose
Nikhil Wagle
Consultant or Advisory Role - Foundation Medicine
Stock Ownership - Foundation Medicine
Scott L. Carter
No relevant relationships to disclose
Antje Sucker
No relevant relationships to disclose
Deborah Norman Farlow
No relevant relationships to disclose
Eran Hodis
No relevant relationships to disclose
Amaro Taylor-Weiner
No relevant relationships to disclose
Carola Berking
Consultant or Advisory Role - Roche
Honoraria - Roche
Other Remuneration - Roche
Friederike Egberts
No relevant relationships to disclose
Jessica Cecile Hassel
No relevant relationships to disclose
Helen Gogas
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche
Ralf Gutzmer
Consultant or Advisory Role - Almirall Hermal GmbH; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Honoraria - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merck Serono; MSD; Novartis; Roche
Research Funding - Novartis; Roche
Other Remuneration - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Simone M. Goldinger
No relevant relationships to disclose
Carmen Loquai
Consultant or Advisory Role - Roche
Honoraria - Roche
Other Remuneration - Roche
Selma Ugurel
Honoraria - Bristol-Myers Squibb; Roche
Lisa Zimmer
Honoraria - Roche
Stacey B. Gabriel
No relevant relationships to disclose
Gad Getz
Consultant or Advisory Role - KEW Group
Levi A. Garraway
Consultant or Advisory Role - Foundation Medicine; Millennium; Novartis
Stock Ownership - Foundation Medicine
Honoraria - Boehringer Ingelheim; Merck
Research Funding - Novartis
Dirk Schadendorf
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Research Funding - Merck